Triple
T2370958
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Herceptin |
E46088
|
entity |
| Predicate | bindsTo |
P37017
|
FINISHED |
| Object | human epidermal growth factor receptor 2 |
E261825
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: human epidermal growth factor receptor 2 | Statement: [Herceptin, bindsTo, human epidermal growth factor receptor 2]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: human epidermal growth factor receptor 2 Context triple: [Herceptin, bindsTo, human epidermal growth factor receptor 2]
-
A.
HER2 receptor
The HER2 receptor is a cell surface protein and member of the epidermal growth factor receptor family that, when overexpressed, drives the growth of certain aggressive breast and other cancers.
-
B.
ERBB2
chosen
ERBB2, also known as HER2, is a receptor tyrosine kinase frequently overexpressed in certain breast and other cancers and serves as a key therapeutic target.
-
C.
EGF
EGF is the ICAO airline designator used to identify American Eagle Airlines in aviation operations and communications.
-
D.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
-
E.
programmed death-ligand 1
Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein expressed on various cells that suppresses T-cell activity by engaging PD-1, enabling tumors to evade immune surveillance.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69a88a145268819083e2736cb835c696 |
completed | March 4, 2026, 7:37 p.m. |
| NER | Named-entity recognition | batch_69abc76f5aec8190867d621e6849258c |
completed | March 7, 2026, 6:36 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69aeb3c81430819081654a90df17c5c0 |
completed | March 9, 2026, 11:49 a.m. |
Created at: March 4, 2026, 7:56 p.m.